STOCKHOLM, Sweden, April 4, 2005 (PRIMEZONE) -- Elekta AB (publ) (Stockholm:EKTAb) today announced the completion of its acquisition of IMPAC Medical Systems, Inc. (Nasdaq:IMPC), following approval of the transaction by IMPAC's stockholders.
Today, April 4, 2005, the stockholders of IMPAC approved the agreement with Elekta to merge IMPAC with a subsidiary of Elekta. Following the merger, which was effective today, IMPAC has become a wholly owned subsidiary of Elekta. Under the terms of the agreement and plan of merger, Elekta will pay USD 24.00 in cash for each share of IMPAC common stock outstanding. Effective today, IMPAC's common stock will no longer trade on the NASDAQ National Market.
IMPAC stockholders who hold their shares directly will receive instructions in the mail describing the process to exchange their IMPAC stock certificates for the cash payment. IMPAC stockholders whose shares are held through intermediaries such as banks or brokers will receive information about their holdings from those institutions.
About Elekta
Elekta is an international medical-technology Group, providing highly advanced clinical solutions for high precision radiation treatment of cancer and for non- or minimally invasive treatment of brain disorders. Clinical solutions include among others Leksell Gamma Knife(R) for non-invasive treatment of brain surgery and Elekta Synergy(R) for image guided radiation therapy (IGRT) as well as associated software systems.
Elekta's systems and solutions are used at over 2,000 hospitals around the world to treat cancer and to diagnose and treat brain disorders, including tumors, vascular malformations and functional disorders.
By developing clinical solutions through close collaborative relationships with clinical partners in research and advanced product development, Elekta is addressing the healthcare system's need for reduced hospitalization costs and also patients' wish for less traumatic treatment options. All of Elekta's solutions employ non-invasive or minimally invasive techniques and are therefore clinically effective, gentle on the patient and cost-effective.
Elekta was founded in 1972 and is headquartered in Stockholm, Sweden. The company is listed on Stockholmsborsen (Stockholm Stock Exchange) under the ticker EKTAb.
More information about Elekta is available at www.elekta.com.
About IMPAC
Founded in 1990, IMPAC is the leading provider of oncology management software and has expanded its core system to include a complete electronic medical record (EMR) for radiation and medical oncology, digital image management, full-featured practice management, laboratory information systems and cancer registry. IMPAC supports the entire team of healthcare professionals who contribute to the care of the cancer patient. In North America, IMPAC's systems are installed in over 1,300 oncology centers, over 1,100 cancer registry operations and over 400 pathology laboratories.
IMPAC also provides the ability to connect to multiple healthcare information and imaging systems via the HL7 and DICOM standards. IMPAC's National Oncology Database(TM) (NODB) is one of the leading comprehensive longitudinal oncology databases available for cancer research today. More information about IMPAC is available at www.impac.com.
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
http://wpy.waymaker.net/client/waymaker1/WOLReleaseFile.aspx?id=85058&fn=wkr0001.pdf